seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Company profile
Ticker
SGEN
Exchange
Website
CEO
Clay B. Siegall
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...
Former names
SEATTLE GENETICS INC /WA
SEC CIK
Corporate docs
Subsidiaries
East Coast Ventures, Inc. • Seagen Australia Pty Limited • Seagen Austria GmbH • Seagen B.V. • Seagen Canada Inc. • Seagen Denmark ApS • Seagen France SAS • Seagen Germany GmbH • Seagen International GmbH • SeaGen International Holdings, LLC ...
IRS number
911874389
SGEN stock data
Latest filings (excl ownership)
8-K
Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal
22 Sep 23
8-K
Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
5 Sep 23
8-K
Other Events
16 Aug 23
S-8
Registration of securities for employees
2 Aug 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Results of Operations and Financial Condition
2 Aug 23
8-K
Other Events
14 Jul 23
8-K
Other Events
14 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
1 Jun 23
8-K
Seagen Stockholders Approve Acquisition by Pfizer
31 May 23
Transcripts
SGEN
Earnings call transcript
2022 Q4
15 Feb 23
SGEN
Earnings call transcript
2022 Q3
28 Oct 22
SGEN
Earnings call transcript
2022 Q2
29 Jul 22
SGEN
Earnings call transcript
2022 Q1
28 Apr 22
SGEN
Earnings call transcript
2021 Q4
10 Feb 22
SGEN
Earnings call transcript
2021 Q3
29 Oct 21
SGEN
Earnings call transcript
2021 Q2
30 Jul 21
SGEN
Earnings call transcript
2021 Q1
1 May 21
SGEN
Earnings call transcript
2020 Q4
12 Feb 21
SGEN
Earnings call transcript
2020 Q3
30 Oct 20
Latest ownership filings
4
ROGER D DANSEY
22 Sep 23
4
VAUGHN B HIMES
22 Sep 23
4
JEAN I LIU
22 Sep 23
4
CHARLES R ROMP
22 Sep 23
4
TODD E SIMPSON
22 Sep 23
144
Notice of proposed sale of securities
21 Sep 23
144
Notice of proposed sale of securities
21 Sep 23
144
Notice of proposed sale of securities
21 Sep 23
144
Notice of proposed sale of securities
21 Sep 23
144
Notice of proposed sale of securities
21 Sep 23
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 309.26 mm | 309.26 mm | 309.26 mm | 309.26 mm | 309.26 mm | 309.26 mm |
| Cash burn (monthly) | 9.26 mm | 5.46 mm | 73.57 mm | 62.67 mm | 58.42 mm | 49.17 mm |
| Cash used (since last report) | 28.07 mm | 16.57 mm | 223.09 mm | 190.03 mm | 177.13 mm | 149.10 mm |
| Cash remaining | 281.19 mm | 292.69 mm | 86.17 mm | 119.23 mm | 132.13 mm | 160.16 mm |
| Runway (months of cash) | 30.4 | 53.6 | 1.2 | 1.9 | 2.3 | 3.3 |
Institutional ownership, Q2 2023
84.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 571 |
| Opened positions | 96 |
| Closed positions | 86 |
| Increased positions | 197 |
| Reduced positions | 188 |
| 13F shares | Current |
|---|---|
| Total value | 30.29 tn |
| Total shares | 157.61 mm |
| Total puts | 13.75 mm |
| Total calls | 7.86 mm |
| Total put/call ratio | 1.7 |
| Largest owners | Shares | Value |
|---|---|---|
| Baker Bros. Advisors | 44.55 mm | $8.57 tn |
| Vanguard | 13.32 mm | $2.56 tn |
| BLK Blackrock | 12.04 mm | $2.32 tn |
| Pentwater Capital Management | 9.63 mm | $1.85 tn |
| Capital World Investors | 9.08 mm | $1.75 tn |
| Capital International Investors | 6.42 mm | $1.23 tn |
| Primecap Management | 6.04 mm | $1.16 tn |
| STT State Street | 3.33 mm | $641.70 bn |
| Wellington Management | 2.25 mm | $433.75 bn |
| JPM JPMorgan Chase & Co. | 2.10 mm | $404.37 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 21 Sep 23 | Simpson Todd E | Common Stock | Sell | Dispose S | No | Yes | 206.5 | 80 | 16.52 k | 128,723 |
| 21 Sep 23 | Charles R Romp | Common Stock | Sell | Dispose S | No | Yes | 206.5 | 45 | 9.29 k | 69,111 |
| 21 Sep 23 | Liu Jean I | Common Stock | Sell | Dispose S | No | Yes | 206.5 | 64 | 13.22 k | 84,398 |
| 21 Sep 23 | Himes Vaughn B | Common Stock | Sell | Dispose S | No | Yes | 206.5 | 80 | 16.52 k | 51,359 |
| 7 Sep 23 | Himes Vaughn B | Common Stock | Sell | Dispose S | No | Yes | 205.76 | 8,785 | 1.81 mm | 51,439 |
| 7 Sep 23 | Himes Vaughn B | Common Stock | Option exercise | Acquire M | No | No | 44.09 | 8,785 | 387.33 k | 60,224 |
| 7 Sep 23 | Himes Vaughn B | NQSO Common Stock | Option exercise | Dispose M | No | No | 44.09 | 8,785 | 387.33 k | 26,447 |
News
If You Invested $100 In This Stock 20 Years Ago, You Would Have $3,400 Today
29 Sep 23
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
27 Sep 23
Seagen Unusual Options Activity
27 Sep 23
Truist Securities Reiterates Hold on Seagen, Maintains $229 Price Target
25 Sep 23
Why Is Seagen Stock Trading Higher Today?
22 Sep 23
Press releases
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
22 Sep 23
MALT Lymphoma Market to witness growth by 2032, estimates DelveInsight | BeiGene, Incyte, Genentech, Sound Biologics, Morphotek, Novartis, Seattle Genetics, Millennium Pharmaceuticals, PersonGen BioTh
18 Sep 23
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
4 Sep 23
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
4 Sep 23
Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
16 Aug 23